ClinicalTrials.Veeva

Menu

Relationship Between Some Vitamins and Antioxidants With in Vitro Fertilization Outcomes

D

Damascus University

Status

Completed

Conditions

In Vitro Fertilization
Infertility

Treatments

Drug: human chorionic gonadotropin

Study type

Observational

Funder types

Other

Identifiers

NCT05393011
UDFP-Biochemistry-01-2022

Details and patient eligibility

About

observation of females condition will getting pregnant by undergoing assisted reproductive technologies, the most important of which is the in vitro fertilization (IVF), where blood and follicular fluid samples are collected from them at the same stage of in vitro fertilization, and then monitor the IVF outcomes until pregnancy occurs or not, based on blood tests. The levels of interested markers in blood and follicular fluid samples of the study individuals are assayed in order to compare these levels with the egg criteria such as egg number and maturation rate and finally compare the results with occurrence or absence of pregnancy.

Full description

Vitamin D, vitamin E, zinc and glutathione peroxidase will be measured in blood and follicular fluid samples of study subjects for women undergoing in vitro fertilization after monitoring their health for two to three months before beginning the first stage of in vitro fertilization. Once start the ovulation induction protocol, which is the first stage of in vitro fertilization, we will monitor all the results from the number of eggs and follicles, their diameter, the thickness of the endometrium, the number of mature eggs, the egg maturation rate and fertilization rate to the occurrence of biochemical pregnancy or not later, based on the blood Human chorionic gonadotropin (hCG) levels two weeks after the embryos transfer to the uterus. The patient is monitored until clinical pregnancy is complete or not. On the other hand, we will later compare the levels of studied parameters with the aforementioned egg quality criteria and with the clinical pregnancy rate of the study group in order to understand the relationship between these studied parameters and the occurrence of pregnancy.

Enrollment

60 patients

Sex

Female

Ages

20 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Cases of Healthy women (in terms of reproductive function).
  • Aged between 20-40 years and were close in terms of education, nutrition, and social status.
  • Explicit male factor such as Oligospermia, Azoospermia, Asthenozoospermia, or TESA (Testicular Sperm Aspiration), ensuring that there is no fertility-interfering female factor.
  • Undergoing long Gonadotropin-releasing hormone (GnRH) agonist down-regulation protocol.

Exclusion criteria

  • Cases classified by the specialist clinician as a female factor such as PCOs (Polycystic Ovary Syndrome), Uterine Fibroids, Uterine Infections, Uterine Adhesions, and Endometriosis.
  • Compound cases.
  • Sex selection cases.
  • Undergoing short GnRH agonist or antagonist protocol.
  • Women aged under 20 or above 40.
  • Women who took nutritional supplements, for at least two to three months before the egg retrieval procedure.
  • Smokers.
  • Cases with the following medical conditions: Tumors, Diabetes, Multiple sclerosis, Autoimmune Diseases, Liver or Kidney Disorders, Cushing's Syndrome, and women who take chronic medications

Trial design

60 participants in 2 patient groups

Pregnant group
Description:
A female is considered pregnant when an explicit gestational sac inside the uterus is seen by ultrasound 4 weeks after embryo transfer.
Treatment:
Drug: human chorionic gonadotropin
Non-pregnant group
Description:
A female is considered not pregnant when no explicit gestational sac is seen inside the uterus by ultrasound 4 weeks after embryo transfer.
Treatment:
Drug: human chorionic gonadotropin

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems